SK hynix likely to get nod for Key Foundry deal soon Deals likely to get regulatory approval from China soon
Translated by Kim So-in 공개 2021-12-20 07:56:32
이 기사는 2021년 12월 20일 07시51분 thebell에 표출된 기사입니다
South Korea’s SK hynix is nearing the completion of its acquisitions of Intel’s NAND flash memory business and the country's leading foundry chip manufacturer Key Foundry as the deals are expected to get antitrust approval from China as early as January 2022.SK hynix filed for approval of the announced business combination with Key Foundry in the U.S., China, and Taiwan through local law firm Kim & Chang, according to industry sources.
The most important factor in the business combination review is whether the combination would substantially restrain competition in that relevant market. SK hynix runs foundry business through SK hynix System IC, but the transaction won’t likely to be subject to competition restriction as a combined market share of its subsidiary and Key Foundry is in a 1% range.
The acquisition would double SK hynix’s foundry production capacity to around 200,000 sheets of wafers per month. According to research firm TrendForce, DB HiTek, which produces 140,000 wafers per month, ranked 10th with a 1% share of the global foundry market. Taiwan's Vanguard International Semiconductor was in the eighth place with a market share in a 1% range, with a monthly capacity of about 240,000 wafers. SK hynix won’t likely exceed 1% market share in the short term even after the acquisition of Key Foundry.
The chipmaker may benefit from a simplified approval process as the business combination is not presumed to have any restrictions on competition. In this case, final results may be announced as early as the end of January.
SK hynix’s acquisition of Intel’s NAND memory business is expected to get antitrust approval in China this week. The chipmaker aims to close the deal before the end of this year.
The transaction already received unconditional approval from seven countries including the U.S. and the EU. (Reporting by Hye-ran Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [i-point]'자가면역질환 신약' 이노보테라퓨틱스, 미국 임상 1상 '성공적'
- [i-point]폴라리스오피스, 엔비디아 ‘커넥트’ 공식 파트너 선정
- [i-point]신성이엔지, 한국종합기술·다스코와 연료전지 발전사업 협약
- [i-point]신테카바이오, 'PEGS 보스턴 2025' 참가
- [AACR 2025]첫 구두발표 진씨커, 경쟁사 넘보는 '유전자가위 액체생검'
- [AACR 2025]이뮨온시아 'CD47' 안전성 굳히기 "경쟁약과 다르다"
- [AACR 2025]항암 신약 항체 대신 '페라틴', 셀레메디 플랫폼 데뷔전
- [AACR 2025]근거 쌓는 '루닛 스코프' 빅파마 공동연구 쇼케이스
- [변곡점 선 콜마비앤에이치]변화의 마지막 카드, 경영진 교체 '강수' 두나
- [변곡점 선 콜마비앤에이치]속절없는 주가 하락 '트리거', 주가 부양 의지 없었나